Analysis of the criteria used for the definition of metabolic syndrome in patients with type 2 diabetes mellitus;Análise dos critérios de definição da síndrome metabólica em pacientes com diabetes melito tipo 2

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 50, Issue 2, 2006, Pages 264-270

  Picon, Paula Xavier ^a   Zanatta, Claudete Maria ^a   Gerchman, Fernando ^a   Zelmanovitz, Themis ^a   Gross, Jorge Luiz ^a   Canani, Luís Henrique ^a  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Diagnostic criteria; Insulin resistance; Metabolic syndrome; National Cholesterol Education Program Adult Treatment Panel III; Type 2 diabetes mellitus; World Health Organization

Indexed keywords

ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PREVALENCE; RISK FACTOR; WORLD HEALTH ORGANIZATION;

CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE; RISK FACTORS; WORLD HEALTH ORGANIZATION;

EID: 33744486609     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/S0004-27302006000200012     Document Type: Article

References (33)

1. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683-9.
2. McNeill AM, Rosamond WD, Girman CJ, Golden SH, Schmidt MI, East HE, et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 2005;28:385-90.
3. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991;14:173-94.
4. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications: Report of WHO a Consultation. Part 1: diagnosis and classification of diabetes mellitus. Genebra, 1999.
5. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 3 A.D.;9(suppl 2):9-21.
6. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
7. Balkau B, Charles MA, Drivsholm T, Borch-Johnsen K, Wareham N, Yudkin JS, et al. Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab 2002;28:364-76.
8. Rantala AO, Kauma H, Lilja M, Savolainen MJ, Reunanen A, Kesaniemi YA. Prevalence of the metabolic syndrome in drug-treated hypertensive patients and control subjects. J Intern Med 1999;245:163-74.
9. Wang JJ, Hu G, Miettinen ME, Tuomilehto J. The metabolic syndrome and incident diabetes: assessment of four suggested definitions of the metabolic syndrome in a Chinese population with high post-prandial glucose. Horm Metab Res 2004;36:708-15.
10. Sone H, Mizuno S, Fujii H, Yoshimura Y, Yamasaki Y, Ishibashi S, et al. Is the diagnosis of metabolic syndrome useful for predicting cardiovascular disease in Asian diabetic patients? Analysis from the Japan diabetes complications study. Diabetes Care 2005;28:1463-71.
11. Rosenbaum P, Gimeno SG, Sanudo A, Franco LJ, Ferreira SR. Analysis of criteria for metabolic syndrome in a population-based study of Japanese-Brazilians. Diabetes Obes Metab 2005;7:352-9.
12. Ferreira SRG, Rosenbaum P, Sanudo A, Gimeno SGA. A modified NCEP criteria to define metabolic syndrome in subjects of Japanese ancestry. Diabetes & Metabolism 2003;29(suppl):4S28-9.
13. Ilanne-Parikka P, Eriksson JG, Lindstrom J, Hamalainen H, Keinanen-Kiukaanniemi S, Laakso M, et al. Prevalence of the metabolic syndrome and its components: findings from a Finnish general population sample and the Diabetes Prevention Study cohort. Diabetes Care 2004;27:2135-40.
14. Bruno G, Merletti F, Biggeri A, Bargero G, Ferrero S, Runzo C, et al. Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study. Diabetes Care 2004;27:2689-94.
15. Bonora E, Targher G, Formentini G, Calcaterra F, Lombardi S, Marini F, et al. The Metabolic Syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study. Diabet Med 2004;21:52-8.
16. Lempiainen P, Mykkanen L, Pyorala K, Laakso M, Kuusisto J. Insulin resistance syndrome predicts coronary heart disease events in elderly nondiabetic men. Circulation 1999;100:123-8.
17. Scheffel RS, Bortolanza D, Weber CS, Costa LA, Canani LH, Santos KG, et al. Prevalência de complicações micro e macrovasculares e de seus fatores de risco em pacientes com diabetes melito do tipo 2 em atendimento ambulatorial. Rev Assoc Med Bras 2004;50:263-7.
18. Isomaa B, Henricsson M, Almgren P, Tuomi T, Taskinen MR, Groop L. The metabolic syndrome influences the risk of chronic complications in patients with type II diabetes. Diabetologia 2001;44:1148-54.
19. Costa LA, Canani LH, Lisboa HR, Tres GS, Gross JL. Aggregation of features of the metabolic syndrome is associated with increased prevalence of chronic complications in type 2 diabetes. Diabet Med 2004;21:252-5.
20. Athyros VG, Mikhailidis DP, Papageorgiou AA, Didangelos TP, Ganotakis ES, Symeonidis AN, et al. Prevalence of atherosclerotic vascular disease among subjects with the metabolic syndrome with or without diabetes mellitus: the METS-GREECE Multicentre Study. Curr Med Res Opin 2004;20:1691-701.
21. WHO Study Group. Diabetes Mellitus. Technical Report Series 727. World Health Organization, 1985.
22. Zelmanovitz T, Gross JL, Oliveira JR, Paggi A, Tatsch M, Azevedo MJ. The receiver operating characteristics curve in the evaluation of a random urine specimen as a screening test for diabetic nephropathy. Diabetes Care 1997;20:516-9.
23. Rose G, Blackburn H, Gillium RT, Prineas RJ. Cardiovascular Survey Methods. WHO Monograph Series, Second Edition, 1982;56:123-9.
24. Coronary Drug Project Research Group. Circulation 1973;(suppl 1):47-8.
25. Kim ES, Han SM, Kim YI, Song KH, Kim MS, Kim WB, et al. Prevalence and clinical characteristics of metabolic syndrome in a rural population of South Korea. Diabet Med 2004;21:1141-3.
26. Ford ES, Giles WH. A comparison of the prevalence of the metabolic syndrome using two proposed definitions. Diabetes Care 2003;26:575-81.
27. Jorgensen ME, Bjerregaard P, Gyntelberg F, Borch-Johnsen K. Prevalence of the metabolic syndrome among the Inuit in Greenland. A comparison between two proposed definitions. Diabet Med 2004;21:1237-42.
28. Marchesini G, Forlani G, Cerrelli F, Manini R, Natale S, Baraldi L, et al. WHO and ATPIII proposals for the definition of the metabolic syndrome in patients with Type 2 diabetes. Diabet Med 2004;21:383-7.
29. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. Available from http://www.idf.org. Accessed 15 August 2005.
30. First International Congress. Prediabetes and the metabolic syndrome. Berlin, Germany, 2005.
31. Takamiya T, Zaky WR, Edmundowics D, Kadowaki T, Ueshima H, Kuller LH, et al. World Health Organization-defined metabolic syndrome is a better predictor of coronary calcium than the adult treatment panel III criteria in American men aged 40-49 years. Diabetes Care 2004;27:2977-9.
32. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356-9.
33. Cossrow N, Falkner B. Race/ethnic issues in obesity and obesity-related comorbidities. J Clin Endocrinol Metab 2004;89:2590-4.